ImpediMed Limited (ASX:IPD)

Market Cap	38.74M -62.5%
Revenue (ttm)	12.72M +23.3%
Net Income	-23.24M
EPS	-0.01
Shares Out	2.04B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,916,199
Average Volume	10,695,998
Open	0.0200
Previous Close	0.0190
Day's Range	0.0170 - 0.0200
52-Week Range	0.0150 - 0.0590
Beta	1.42
RSI	39.12
Earnings Date	Jan 28, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 77
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IPD

Financial Performance

In fiscal year 2025, ImpediMed's revenue was 12.72 million, an increase of 23.31% compared to the previous year's 10.32 million. Losses were -23.24 million, 17.4% more than in 2024.